We rank companies based on fund manager, research analyst and news sentiment
GRCL

Gracell Biotechnologies Inc. American Depositary Shares
GRCL

 

About: Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with its proprietary technology platforms-FasTCAR and TruUCAR.

Employees: 314

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 5 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

308% more capital invested

Capital invested by funds: $135M [Q3] → $552M (+$417M) [Q4]

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

67% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 5 (+2) [Q4]

38% more funds holding

Funds holding: 45 [Q3] → 62 (+17) [Q4]

0.99% more ownership

Funds ownership: 10.51% [Q3] → 11.5% (+0.99%) [Q4]

60% less call options, than puts

Call options by funds: $213K | Put options by funds: $531K

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$10
Avg. target
$10.25
High target
$11

5 analyst ratings

positive
20%
neutral
80%
negative
0%
Stifel
Benjamin Burnett
$10.25
Hold
Downgraded
22 Feb 2024
Wells Fargo
Yanan Zhu
$10
Equal-Weight
Downgraded
27 Dec 2023
Piper Sandler
Joseph Catanzaro
$10
Neutral
Downgraded
27 Dec 2023
HC Wainwright & Co.
Emily Bodnar
$10
Neutral
Downgraded
26 Dec 2023
Stifel
Benjamin Burnett
$11
Buy
Initiated
19 Oct 2023

Financial journalist opinion

Neutral
GlobeNewsWire
1 month ago
Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the “EGM”) held on February 19, 2024, the Company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent (“Merger Sub”), the Plan of Merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”), and the other agreements or documents contemplated by the Merger Agreement or any document or instrument delivered in connection thereunder (the “Transaction Documents”) to which the Company is a party and the consummation of the transactions contemplated by the Merger Agreement (including the Merger) and the Contingent Value Rights Agreement, in the form attached as Exhibit B to the Merger Agreement, (collectively, the “Transactions”), upon the terms and subject to the conditions set forth therein. Pursuant to the Merger Agreement, in accordance with the applicable provisions of the Companies Act (As Revised) of the Cayman Islands, Merger Sub will merge with and into the Company at the effective time of the Merger, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the “Merger”).
Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement
Neutral
GlobeNewsWire
3 months ago
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform Gracell shareholders to receive $2.00 per ordinary share (equivalent to $10.00 per American Depositary Share (ADS)) in cash at closing, plus a non-tradable contingent value right (CVR) for up to $0.30 per ordinary share (equivalent to $1.50 per ADS), representing a total transaction value of up to $1.2 billion including the CVR SAN DIEGO and SUZHOU, China and SHANGHAI, China, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, today announced it has entered into a definitive agreement to be acquired by AstraZeneca. The proposed acquisition will enrich AstraZeneca's growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T (CAR-T) cell therapy, a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases including systemic lupus erythematosus (SLE).
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases